Translating Evidence-Based Research into Value-Based Decisions in Oncology

Published Online: Tuesday, November 20, 2012
Follow Pharmacy_Times:
At a meeting hosted by the American Journal of Managed Care, key figures in the managed care industry discussed innovative payment models being utilized by payers and providers.
On Friday, November 16, 2012, the American Journal of Managed Care hosted its first annual live meeting, “Translating Evidence-Based Research into Value-Based Decisions in Oncology.” The meeting, which brought together stakeholders from all sides of the managed care industry, provided an arena for health care professionals to discuss new, innovative payment models being utilized by both payers and providers.
 
To view highlights from the meeting, click here.

Related Articles
Citing a risk of spreading unsuspected cancer, the FDA is advising against the use of laparoscopic power morcellators in the removal of the uterus or fibroids in the majority of women.
Amgen has discontinued its studies on rilotumumab in advanced gastric cancer after an increased number of deaths were reported among patients receiving rilotumumab and chemotherapy, compared with those only undergoing chemotherapy.
Clinical practice guidelines for the diagnosis and treatment of certain types of cancer are surprisingly unstandardized.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Latest Issues
$auto_registration$